Suzhou Ribo Life Science Co. Ltd. (Ribo), a siRNA drug development company in China, announced today that it has raised RMB203 million (US$28.78 million) in a series C1 round of financing led by Panlin Capital and Trinity Innovation Fund.
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription?